Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
10 July 2020Website:
http://poseida.comNext earnings report:
07 March 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Thu, 21 Nov 2024 21:20:41 GMTDividend
Analysts recommendations
Institutional Ownership
PSTX Latest News
Does Poseida Therapeutics, Inc. (PSTX) have what it takes to be a top stock pick for momentum investors? Let's find out.
SAN DIEGO , Nov. 11, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune and rare diseases, today announced that the Company will participate in the following upcoming investor conferences: Stifel 2024 Healthcare Conference Date: Monday, November 18, 2024 Time: 10:20am ET Piper Sandler 36th Annual Healthcare Conference Date: Wednesday, December 4, 2024 Time: 12:00pm ET Webcasts will be available on the Investors & Media Section of Poseida's website, www.poseida.com. A replay of the webcast will be available for approximately 90 days following the presentation.
Inclusion on list recognizes Poseida for employee sentiment and satisfaction SAN DIEGO , Oct. 3, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, today announced its inclusion in Newsweek Magazine's annual America's Top Most Loved Workplaces® list, developed by Most Loved Workplace®, a division of Best Practice Institute (BPI). "At Poseida, our employees are essential to achieving our mission to boldly develop a new class of cell and gene therapies with the capacity to cure," said Kristin Yarema, Ph.D.
Poseida Therapeutics shows promising early results in myeloma with their BCMA-directed allogeneic CAR T-cell therapy, achieving a 60% response rate in phase 1 trials. Financially stable with $30.5 million in cash, $207.3 million in short-term investments, and a $20 million milestone payment from Roche extending their cash runway. Strong partnerships with big pharma and deep cash reserves provide a solid foundation for continued development and potential non-dilutive funding.
SAN DIEGO , Aug. 29, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, today announced that the Company will participate in fireside chats at the following upcoming investor conferences in September: H.C. Wainwright 26th Annual Global Investment Conference Date: Monday, September 9, 2024 Time: 10:30am ET 2024 Cantor Global Healthcare Conference Date: Tuesday, September 17, 2024 Time: 1:20pm ET Live webcasts of the fireside chats will be available on the Investors & Media Section of Poseida's website, www.poseida.com.
Poseida Therapeutics, Inc. (PSTX) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.32 per share a year ago.
Does Poseida Therapeutics, Inc. (PSTX) have what it takes to be a top stock pick for momentum investors? Let's find out.
SAN DIEGO , July 1, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, today announced that the Company's President and Chief Executive Officer, Kristin Yarema, Ph.D., will participate in a virtual fireside chat at the Stifel 2024 Virtual Cell Therapy Forum on Tuesday, July 9, 2024 at 7:55am PT | 10:55am ET.
SAN DIEGO , June 3, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, today announced that its virtual Annual Meeting of Stockholders (the "Annual Meeting") will be held on Monday, June 17, 2024 at 1:00 p.m. PT. The Annual Meeting will be held through a live webcast.
Additional results from the phase 1 study, using P-BCMA-ALLO1 for the treatment of patients with relapsed/refractory multiple myeloma, are expected at AACR on April 8th of 2024; Other data 2nd half of 2024. The global multiple myeloma market size is projected to reach $31 billion by 2026. Allogenic off-the-shelf CAR-T technology has already garnered strategic investment interest from Astellas and a collaboration agreement with Roche.
What type of business is Poseida Therapeutics?
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications. It is also involved in the development of P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers; P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in preclinical development for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC); and P-PSMA-101, an allogeneic CAR-T product candidate under Phase 1 clinical trial for treating mCRPC. In addition, the company engages in the development of P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; P-OTC-101, a clinical stage liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; and P-PAH-101, a clinical stage liver-directed gene therapy for the in vivo treatment of phenylketonuria. It has a research collaboration and license agreement with F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.
What sector is Poseida Therapeutics in?
Poseida Therapeutics is in the Healthcare sector
What industry is Poseida Therapeutics in?
Poseida Therapeutics is in the Biotechnology industry
What country is Poseida Therapeutics from?
Poseida Therapeutics is headquartered in United States
When did Poseida Therapeutics go public?
Poseida Therapeutics initial public offering (IPO) was on 10 July 2020
What is Poseida Therapeutics website?
https://poseida.com
Is Poseida Therapeutics in the S&P 500?
No, Poseida Therapeutics is not included in the S&P 500 index
Is Poseida Therapeutics in the NASDAQ 100?
No, Poseida Therapeutics is not included in the NASDAQ 100 index
Is Poseida Therapeutics in the Dow Jones?
No, Poseida Therapeutics is not included in the Dow Jones index
When was Poseida Therapeutics the previous earnings report?
No data
When does Poseida Therapeutics earnings report?
The next expected earnings date for Poseida Therapeutics is 07 March 2025